
doi: 10.1101/2020.10.29.360040 , 10.1038/s41467-021-22700-4 , 10.17863/cam.69923 , 10.17863/cam.69731 , 10.17863/cam.71261
pmid: 33976138
pmc: PMC8113504
handle: 11343/278243
doi: 10.1101/2020.10.29.360040 , 10.1038/s41467-021-22700-4 , 10.17863/cam.69923 , 10.17863/cam.69731 , 10.17863/cam.71261
pmid: 33976138
pmc: PMC8113504
handle: 11343/278243
AbstractShigella sonneiis the most common agent of shigellosis in high-income countries, and causes a significant disease burden in low- and middle-income countries. Antimicrobial resistance is increasingly common in all settings. Whole genome sequencing (WGS) is increasingly utilised forS. sonneioutbreak investigation and surveillance, but comparison of data between studies and labs is challenging. Here, we present a genomic framework and genotyping scheme forS. sonneito efficiently identify genotype and resistance determinants from WGS data. The scheme is implemented in the software package Mykrobe and tested on thousands of genomes. Applying this approach to analyse >4,000S. sonneiisolates sequenced in public health labs in three countries identified several common genotypes associated with increased rates of ciprofloxacin resistance and azithromycin resistance, confirming intercontinental spread of highly-resistantS. sonneiclones and demonstrating the genomic framework can facilitate monitoring of the emergence and spread of resistant clones at local and global scales.
Shigella sonnei/classification, /631/326/325/2482, Drug Resistance, Bacterial/genetics, Azithromycin, Global Health, /631/114/1386, Ciprofloxacin, Azithromycin/pharmacology, Drug Resistance, Multiple, Bacterial, /631/181/757, /692/308/174, Phylogeny, Genome, Geography, Q, article, Single Nucleotide, Genomics, Anti-Bacterial Agents, England, Multiple, Genotype, Science, Population, 610, Shigella sonnei, /45/23, Microbial Sensitivity Tests, Polymorphism, Single Nucleotide, Ciprofloxacin/pharmacology, Article, Anti-Bacterial Agents/pharmacology, Dysentery, SDG 3 - Good Health and Well-being, Bacillary/diagnosis, 616, Genetics, Humans, Polymorphism, Dysentery, Bacillary, Whole Genome Sequencing, Australia, Genome, Bacterial/genetics, United States, Genomics/methods, Drug Resistance, Multiple, Bacterial/genetics, Genetics, Population, Microbial Sensitivity Tests/methods, Dysentery, Bacillary/diagnosis, Genome, Bacterial
Shigella sonnei/classification, /631/326/325/2482, Drug Resistance, Bacterial/genetics, Azithromycin, Global Health, /631/114/1386, Ciprofloxacin, Azithromycin/pharmacology, Drug Resistance, Multiple, Bacterial, /631/181/757, /692/308/174, Phylogeny, Genome, Geography, Q, article, Single Nucleotide, Genomics, Anti-Bacterial Agents, England, Multiple, Genotype, Science, Population, 610, Shigella sonnei, /45/23, Microbial Sensitivity Tests, Polymorphism, Single Nucleotide, Ciprofloxacin/pharmacology, Article, Anti-Bacterial Agents/pharmacology, Dysentery, SDG 3 - Good Health and Well-being, Bacillary/diagnosis, 616, Genetics, Humans, Polymorphism, Dysentery, Bacillary, Whole Genome Sequencing, Australia, Genome, Bacterial/genetics, United States, Genomics/methods, Drug Resistance, Multiple, Bacterial/genetics, Genetics, Population, Microbial Sensitivity Tests/methods, Dysentery, Bacillary/diagnosis, Genome, Bacterial
| selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | 96 | |
| popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network. | Top 1% | |
| influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | Top 10% | |
| impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network. | Top 1% |
